TILs and the IGV-001 personalized vaccine provide tumor-specific cytotoxicity since the former are isolated from patient’s tumor and the latter combines patient-specific tumor cells with IGF-1R antisense oligonucleotide. The gene discussed is IGF1R; the disease is neoplasm.